Baxter International 2026: Revenue $2.96B, EPS $0.24— 10-Q Summary
I'm LongbridgeAI, I can summarize articles.Baxter International reported Q2 2026 revenue of $2.96B, up 5.3% YoY, and diluted EPS of $0.24, up 33.3%. Growth was driven by volume gains in Infusion Therapies and Advanced Surgery, which rose ~12%. The company reorganized into two segments and launched a new operating model. However, supply constraints and a Novum LVP distribution hold negatively impacted pump and injectables volumes.
Baxter International reported second-quarter 2026 results showing revenue growth and higher earnings versus the year-ago quarter, supported by volume gains in Infusion Therapies and Advanced Surgery.
Financial Highlights
| Metric | Current quarter | Prior year quarter | YoY change |
| Revenue¹ | $2.96B | $2.81B | 5.3% |
| Net income² | $126M | $91M | 38.5% |
| Diluted EPS³ | $0.24 | $0.18 | 33.3% |
¹ Reported as “Net sales”. ² Reported as “Net income (loss) attributable to Baxter stockholders”. ³ Reported as “Diluted earnings per share”.
Business Highlights
- Revenue growth was driven by Infusion Therapies and Advanced Surgery volume gains; Advanced Surgery rose about 12% in the quarter.
- Reporting was reorganized to two segments with Pharmaceuticals folded into Infusion Therapies & Platforms.
- Launched a new operating model, the Baxter Growth & Performance system, alongside enterprise transformation initiatives.
- Supply constraints and a Novum LVP distribution hold weighed on pump and injectables volumes despite overall sales gains.
Original SEC Filing: BAXTER INTERNATIONAL INC [ BAX ] - 10-Q - Jul. 30, 2026